At a glance
- Originator AstraZeneca
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Intermittent claudication; Myocardial ischaemia
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 21 Feb 1995 Discontinued-Unspecified phase for Intermittent claudication in United Kingdom (Unknown route)
- 21 Feb 1995 Discontinued-Unspecified phase for Myocardial ischaemia in United Kingdom (Unknown route)